COVID-19 ŞÜPHESİYLE BAŞVURAN HASTALARDA BAŞ AĞRISI ÖZELLİKLERİNİN DEĞERLENDİRİLMESİ

Amaç: Bu çalışmada COVID-19 enfeksiyonunda baş ağrısı sıklığını ve hastalığa özgü olup olmadığını belirlemek amaçlanmıştır. Materyal ve Metot: Kesitsel tanımlayıcı araştırmaya COVID Polikliniğine başvuran 18 yaş üstü tüm hastalar dahil edilmiştir. Hastalardan baş ağrısı şikayeti varlığı ve özelliklerine yönelik 18 soru yanıtlamaları istenmiştir. Bağ ağrısı tanı gruplarını ayırmak için ID MIGREN ölçeği ve Uluslararası Baş Ağrısı Cemiyeti tanı kriterleri, ağrı yoğunluğu için Vizüel Ağrı Skalası kullanılmıştır. Bulgular: Çalışma 440 katılımcıdan 208’i (%47,27) kadındı. 273 ilk başvuru hastasından 44’ünde (%16,12) pozitif RT-PCR sonucu alınmıştı. Başvuruları herhangi bir şikayete dayalı olan 301 hastadan 179’unun (%59,47) baş ağrısı şikayetleri bulunuyordu. VAS’a göre ağrı yoğunluğu 5,86 ± 2,72 idi. Baş ağrısı bulunma oranları ya da ağrı yoğunluğu RT-PCR test sonuçları açısından anlamlı farklılık göstermiyordu. Baş ağrısı tanı grupları açısından RT-PCR test sonuçlarına göre anlamlı farklılık yoktu. Sonuç: Baş ağrısı COVID-19 hastalarında en sık yakınmalardan biridir. Çalışmamızda COVID-19 polikliniğine hastalık şüphesi ile başvuran hastalardan RT-PCR testi ile tanı alan ve almayan hastalar arasında baş ağrısı şikayetinin sıklık ve özelliklerinde farklılık yoktur.

EVALUATION OF HEADACHE CHARACTERISTICS IN PATIENTS PRESENTING WITH SUSPECTED COVID-19

Objectives: This study aimed to determine the frequency of headaches in COVID-19 related hospital admissions and whether they are specific to the disease. Materials and Methods: All patients over the age of 18 who applied to the COVID Outpatient Clinic were included in the cross-sectional descriptive study. Patients were asked to answer an 18-item questionnaire about the presence and characteristics of headache complaints. The ID Migraine scale and International Headache Society diagnostic criteria were used for classification, and the visual Pain Scale was used for pain intensity. Results: Of the 440 participants, 208 (47.27%) were women. Of the 273 first applicant patients, 44 (16.12%) had positive RT-PCR results. Of the 301 patients whose applications were based on any complaint, 179 (59.47%) had headaches. According to VAS, the pain intensity was 5.86 ± 2.72. Rates of headache presence or pain intensity did not differ in terms of RT-PCR test results. There was no significant difference in headache diagnostic groups according to RT-PCR test results. Conclusion: A headache is one of the most common complaints in COVID-19 patients. In our study, there was no difference in the frequency and characteristics of headaches according to RT-PCR test among patients who applied to the COVID-19 outpatient clinic with suspicion of the illness.

PDF

___

1. Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. Neurologic manifestations of hospitalized patients with Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol 2020;77(6):683-90. (doi:10.1001/jamaneurol.2020.1127)
2. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J,et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Corona virus-infected pneumonia in Vuhan, China. JAMA 2020;323:1061-9. (doi:10.1001/jama.2020.1585)
3. Vacchiano V, Riguzzi P, Volpi L, Tappata M, Avoni P, Rizzo G,et al. Early neurological manifestations of hospitalized COVID-19 patients. NeurolSci 2020;41:2029–31. (doi:10.1007/s10072-020-04525-z)
4. Bolay H, Gul A, Baykan B. COVID-19 is a real headache! Headache 2020;60:1415–21.(doi: 10.1111/head.13856)
5. Toptan T, Aktan C, Basari A, Bolay H. Case series of headache characteristics in COVID-19; headache can be an isolated symptom. Headache 2020;60(8):1788–92. (doi:10.1111/head.13940)
6. Karadas O, Ozturk B, Sonkaya AR. A prospective clinical study of detailed neurological manifestations in patients with COVID-19. Neurol Sci 2020;41(8):1991–5. (doi:10.1007/s10072-020-04547-7)
7. Hughes C, Nichols T, Pike M, Subbe C, Elghenzai S. Cerebralvenoussinusthrombosis as a presentation of COVID-19. Eur J Case Rep Intern Med 2020;7(5):001691. (doi:10.12890/2020_001691)
8. Lipton RB, Dodick D, SadovskyR, KolodnerK, EndicottJ, Hettiarachchi J. A self-administered screener for migraine in primary care: theIDmigrainevalidationstudy. Neurology2003;61(3):375-82.(doi:10.1212/01.wnl.0000078940.53438.83)
9. Siva A, Zarifoğlu M. Validity of the Turkish ID Migrainescreener in workers and the impact of migraine on productivity. Cephalalgia2005;25:863-5.
10. HeadacheClassificationCommittee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia 2018;38:1‐211. (doi:10.1177/0333102417738202)
11. Wu Y, Xu X, Chen Z, Duan J, Hashimoto K, Yang L, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. Brain Behav Immun 2020;87:18-22. (doi:10.1016/j.bbi.2020.03.031)
12. Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q,et al. Clinical and epidemiological characteristics of 1,420 European patients with mild to-moderate Corona virus Disease 2019. J InternMed 2020;288(3):335-44. (doi:10.1111/joim.13089)
13. Lippi G, Mattiuzzi C, Bovo C, Henry BM. Headache is an important symptom in patients with corona virus disease 2019 (COVID-19). Diagnosis (Berl) 2020;7(4):409-11. (doi:10.1515/dx-2020-0048)
14. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J MedVirol 2020;92(10):1902-14. (doi:10.1002/jmv.25884)
15. Borges do Nascimento IJ, Cacic N, Abdulazeem HM, vonGroote TC, Jayarajah U, Weerasekara I, et al. Novel Coronavirus Infection (COVID-19) in humans: a scoping review and meta-analysis. J ClinMed 2020;9(4):941. (doi:10.3390/jcm9040941)
16. Edvinsson L, Haanes KA, Warfvinge K. Does inflammation have a role in migraine? Nat Rev Neurol 2019;15:483‐90. (doi:10.1038/s41582-019-0216-y)
17. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endothelitis in COVID‐19. Lancet 2020;395:1417‐8. (doi:10.1016/S0140-6736(20)30937-5)
18. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias, and facial pain. 2nd edn. Cephalalgia 2004;24:1–160